Inhibition of hiv infection through chemoprophylaxis

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/675 (2006.01) A61K 31/506 (2006.01) A61K 31/513 (2006.01) A61K 31/52 (2006.01) A61K 31/522 (2006.01) A61K 31/7072 (2006.01) A61K 31/7076 (2006.01) A61K 31/708 (2006.01) A61P 31/18 (2006.01)

Patent

CA 2641388

A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self- replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.

L'invention concerne un procédé visant à protéger un hôte primate contre une infection à autoréplication par un rétrovirus de l'immunodéficience. Pour ce faire, on administre à l'hôte primate une combinaison d'une dose pharmaceutiquement efficace d'un inhibiteur nucléosidique de la transcriptase inverse et d'une dose pharmaceutiquement efficace d'un inhibiteur nucléotidique de la transcriptase inverse, avant l'exposition au rétrovirus de l'immunodéficience. L'administration est efficace si elle est fournie par une dose unique dans les 24 heures avant l'exposition. Un régime de doses journalières régulières confère aussi efficacement une protection contre un rétrovirus de l'immunodéficience qui s'autoréplique après avoir infecté un hôte primate. Le procédé de lutte contre la transmission d'un rétrovirus dans une population consiste à administrer la combinaison décrite à une sous-population présentant un risque élevé de contracter une infection rétrovirale de l'immunodéficience, avant l'exposition sexuelle à une source de rétrovirus de l'immunodéficience, afin d'empêcher l'autoréplication dudit rétrovirus chez un membre de la sous-population.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Inhibition of hiv infection through chemoprophylaxis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of hiv infection through chemoprophylaxis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of hiv infection through chemoprophylaxis will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1538380

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.